E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic, inherited blood disorder that impacts haemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040644 |
E.1.2 | Term | Sickle cell disease |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the efficacy of two dosing regimens of oral decitabine-tetrahydrouridine (NDec) combination as measured by improvement in haemoglobin compared to placebo in hydroxyurea (HU)-non-eligible patients with sickle cell disease (SCD). |
|
E.2.2 | Secondary objectives of the trial |
1. To investigate the safety and tolerability of NDec in HU-non-active patients with SCD compared to placebo 2. To evaluate clinical efficacy measures of NDec in HU-non-active patients with SCD compared to placebo 3. To further describe the pharmacokinetics and pharmacodynamics of NDec in HU-non-active patients with SCD |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age above or equal to 18 years at the time of signing informed consent • Confirmed diagnosis of SCD (including HbSS, HbSC, HbSβ0 thalassaemia and HbSβ+ thalassaemia) • 2–10 episodes of documented VOCs within the last 12 months prior to the screening visit • Haemoglobin ≥5.0 g/dL and ≤10.5 g/dL at visit 1 • Reticulocyte count >1.5 x ULN at visit 1 • Body weight 40 to 125 kg (inclusive) |
|
E.4 | Principal exclusion criteria |
• Patient is on chronic transfusion therapy as defined by receiving scheduled (pre-planned) series of blood transfusion (simple or exchange) for prophylactic purposes, or the patient is likely to begin chronic transfusion therapy during the course of the trial, or has received RBC or whole blood transfusion for any reason within 28 days of visit 1 • Receipt of erythropoietin or other haematopoietic growth factor treatment within 28 days of signing ICF, or planned treatment with these agents during the trial • Receipt of voxelotor, crizanlizumab or L-glutamine treatment within 12 weeks of signing the informed consent form, or planned treatment with such agents during the trial • Platelet count >800 x 109/L at visit 1 • Absolute neutrophil count <1.5 x 10^9/L at visit 1 • Any condition/concurrent chronic disease involving the stomach or small intestine which may affect drug absorption, as per investigator's judgement • Female who is pregnant, breast-feeding or intends to become pregnant within 6 months after the final trial product administration or is of child-bearing potential and not using highly effective methods of contraception (or adequate contraceptive measures as required by local regulation or practice) starting at screening and throughout the trial period and for 6 months after the last dose of trial product • Male of reproductive age with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure (or adequate contraceptive measure as required by local regulation or practice) from trial start to: o Six (6) months after the last dose of trial product for patients on NDec/Placebo o Six (6) months after the last dose of trial product for patients outside US and CA randomised to HU o Twelve (12) months after the last dose of trial product for patients randomised to HU in US and CA |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in total haemoglobin |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline (week 0) to week 24 |
|
E.5.2 | Secondary end point(s) |
PK/PD endpoints: 1. Cmax for decitabine from pharmacokinetic assessment 2. Cmax for tetrahydrouridine from pharmacokinetic assessment 3. Change in DNMT1 activity 4. Change in CDA activity
Efficacy endpoints: 5. Change in foetal haemoglobin (g/dL) 6. Change in foetal haemoglobin as a proportion of total haemoglobin (%HbF) 7. Change in F-cell level as a proportion of total RBC (%F-cells) 8. Change in haemolysis measure: absolute reticulocyte count 9. Change in haemolysis measure: indirect bilirubin 10. Change in haemolysis measure: lactate dehydrogenase 11. Number of vaso-occlusive crises 12. Number of acute chest syndrome 13. Number of RBC units transfused
Safety endpoint: 14. Number of adverse events of grade 3 or higher |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. & 2. At week 24 3. - 10. From baseline (week 0) to week 24 11. - 13. From baseline (week 0) to week 48 14. From baseline (week 0) to week 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Double-dummy with one additional open-label arm |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Different treatment regimen and placebo |
|
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
India |
South Africa |
Turkey |
United Kingdom |
United States |
European Union |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 2 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 26 |